NCT05859477View on ClinicalTrials.gov

Nivolumab in Combination With Chemotherapy for FGFR2-positive Metastatic Gastric Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

June 5, 2022

Primary Completion Date

December 1, 2023

Study Completion Date

December 1, 2024

Conditions
Metastatic Gastric CancerPD-L1 Gene AmplificationFGFR2 Amplification
Interventions
DRUG

Nivolumab

360 mg, i.v., every 3 weeks

DRUG

Capecitabine

capecitabine 1000 mg/m², orally, twice a day, days 1-14 of each cycle

DRUG

Oxaliplatin

130 mg/m², i.v., day 1, every 3 weeks

Trial Locations (1)

10032

RECRUITING

Bureau for Cancer Research, New York

All Listed Sponsors
lead

Kidney Cancer Research Bureau

OTHER